List of Figures
Figure 1: Psoriasis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products 39
Figure 2: Pipeline for Psoriasis Therapeutics, Global, 2018 42
Figure 3: Pipeline for Psoriasis Therapeutics by Molecular Target, Global, 2018 44
Figure 4: Psoriasis Therapeutics Market, APAC, Tildrakizumab Forecast ($m), 2018–2024 46
Figure 5: Psoriasis Therapeutics Market, APAC, Risankizumab Forecast ($m), 2019–2024 48
Figure 6: Psoriasis Therapeutics Market, APAC, Bimekizumab Forecast ($m), 2022–2024 51
Figure 7: Psoriasis Therapeutics Market, APAC, Certolizumab Pegol Market ($m), 2021–2024 53
Figure 8: Psoriasis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products 54
Figure 9: Psoriasis Therapeutics Market, Competitor Matrix for Psoriasis Marketed and Pipeline Products 55
Figure 10: Psoriasis Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2007–2017 57
Figure 11: Psoriasis Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2007–2017 58
Figure 12: Psoriasis Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2007–2017 59
Figure 13: Psoriasis Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2007–2017 60
Figure 14: Psoriasis Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2007–2017 61
Figure 15: Psoriasis Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2007–2017 62
Figure 16: Psoriasis Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2007–2017 63
Figure 17: Psoriasis Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2007–2017 64
Figure 18: Psoriasis Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2007–2017 65
Figure 19: Psoriasis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 65
Figure 20: Psoriasis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 66
Figure 21: Psoriasis Therapeutics Market, Asia Pacific, Treatment Usage Patterns (‘000), 2017–2024 68
Figure 22: Psoriasis Therapeutics Market, Asia Pacific, Market Size ($m), 2017–2024 69
Figure 23: Psoriasis Therapeutics Market, India, Treatment Usage Patterns (’000), 2017–2024 70
Figure 24: Psoriasis Therapeutics Market, India, Annual Cost of Therapy ($), 2017–2024 71
Figure 25: Psoriasis Therapeutics Market, India, Market Size ($m), 2017–2024 72
Figure 26: Psoriasis Therapeutics Market, China, Treatment Usage Patterns (‘000), 2017–2024 73
Figure 27: Psoriasis Therapeutics Market, China, Annual Cost of Therapy ($), 2017–2024 74
Figure 28: Psoriasis Therapeutics Market, China, Market Size ($m), 2017–2024 75
Figure 29: Psoriasis Therapeutics Market, Australia, Treatment Usage Patterns (‘000), 2017–2024 76
Figure 30: Psoriasis Therapeutics Market, Australia, Annual Cost of Therapy ($), 2017–2024 77
Figure 31: Psoriasis Therapeutics Market, Australia, Market Size ($m), 2017–2024 78
Figure 32: Psoriasis Therapeutics Market, South Korea, Treatment Usage Patterns (‘000), 2017–2024 79
Figure 33: Psoriasis Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017–2024 79
Figure 34: Psoriasis Therapeutics Market, South Korea, Market Size ($m), 2017–2024 80
Figure 35: Psoriasis Therapeutics Market, Japan, Treatment Usage Patterns (‘000), 2017–2024 81
Figure 36: Psoriasis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2017–2024 82
Figure 37: Psoriasis Therapeutics Market, Japan, Market Size ($m), 2017–2024 83
Figure 38: Psoriasis Therapeutics Market, Global, Licensing Deals by Region and Value, 2007–2017 88
Figure 39: Psoriasis Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007–2017 89
Figure 40: Psoriasis Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007–2017 90
Figure 41: Psoriasis Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2007–2017 91
Figure 42: Psoriasis Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2007–2017 92
Figure 43: Psoriasis Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2007–2017 94
Figure 44: Psoriasis Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007–2017 95
Figure 45: Psoriasis Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007–2017 96
Figure 46: Psoriasis Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2007–2017 97
Figure 47: Psoriasis Therapeutics Market, Global, Co-development Deals by Molecular Target, 2007–2017 98